Skip to main content
SpringerLink
Log in

Increasing use of ranibizumab [Lucentis; Genentech, Novartis Opthalmics] will drive robust growth in the AMD* market

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources.Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe. Media Release: 10 Mar 2009. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Increasing use of ranibizumab [Lucentis; Genentech, Novartis Opthalmics] will drive robust growth in the AMD* market. Pharmacoecon. Outcomes News 574, 11 (2009). https://doi.org/10.2165/00151234-200905740-00027

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905740-00027

Keywords

Search

Navigation